Publications & Conferences
Selected Publications
Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy.
Farias RM, Jiang Y, Levy EJ, Hwang C, Wang J, Burton EM, Cohen L, Ajami N, Wargo JA, Daniel CR, McQuade JL. BMC Cancer. 2024 Dec 4;24(1):1493. doi: 10.1186/s12885-024-13234-1.
Melanoma and microbiota: Current understanding and future directions.
Routy B, Jackson T, Mählmann L, Baumgartner CK, Blaser M, Byrd A, Corvaia N, Couts K, Davar D, Derosa L, Hang HC, Hospers G, Isaksen M, Kroemer G, Malard F, McCoy KD, Meisel M, Pal S, Ronai Z, Segal E, Sepich-Poore GD, Shaikh F, Sweis RF, Trinchieri G, van den Brink M, Weersma RK, Whiteson K, Zhao L, McQuade J, Zarour H, Zitvogel L. Cancer Cell. 2024 Jan 8;42(1):16-34. doi: 10.1016/j.ccell.2023.12.003.
Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial.
Zhang X, Irajizad E, Hoffman KL, Fahrmann JF, Li F, Seo YD, Browman GJ, Dennison JB, Vykoukal J, Luna PN, Siu W, Wu R, Murage E, Ajami NJ, McQuade JL, Wargo JA, Long JP, Do KA, Lampe JW, Basen-Engquist KM, Okhuysen PC, Kopetz S, Hanash SM, Petrosino JF, Scheet P, Daniel CR. EBioMedicine. 2023 Dec;98:104873. PMID: 38040541; PMCID: PMC10755114.
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA).
Wei AZ, Chen LN, Orloff M, Ariyan CE, Asgari M, Barker CA, Buchbinder E, Chandra S, Couts K, Frumovitz MM, Futreal A, Gershenwald JE, Hanna EY, Izar B, LeBlanc AK, Leitao MM Jr, Lipson EJ, Liu D, McCarter M, McQuade JL, Najjar Y, Rapisuwon S, Selig S, Shoushtari AN, Yeh I, Schwartz GK, Guo J, Patel SP, Carvajal RD.Pigment Cell Melanoma Res. 2023 Nov;36(6):542-556. doi: 10.1111/pcmr.13139. Epub 2023 Oct 7. PMID: 37804122
Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma.
Witt RG, Cass SH, Tran T, Damania A, Nelson EE, Sirmans E, Burton EM, Chelvanambi M, Johnson S, Tawbi HA, Gershenwald JE, Davies MA, Spencer C, Mishra A, Wong MC, Ajami NJ, Peterson CB, Daniel CR, Wargo JA, McQuade JL**; Nelson KC**. JAMA Dermatol. 2023 Oct 1;159(10):1076-1084. PMID: 37647056; PMCID: PMC10469295. **Co-last author
Bodywide ecological interventions on cancer.
Kroemer, G., McQuade, J.L., Merad, M. et al. Nat Med 29, 59–74 (2023). doi:10.1038/s41591-022-02193-4.
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.
Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Vashisht Gopal YN, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Clin Cancer Res. 2023 Jan 4;29(1):154-164. PMID: 36166093; PMCID: PMC10311539.
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.
McQuade JL, Hammers H, Furberg H, Engert A, André T, Blumenschein G Jr, Tannir N, Baron A, Larkin J, El-Khoueiry A, Carbone
DP, Thomas JM, Hennicken D, Coffey M, Motzer RJ. JAMA Oncol. 2023 Jan 1;9(1):102-111. doi: 10.1001/jamaoncol.2022.5409
Body-mass index and survival after cancer diagnosis: A pan-cancer cohort study of 114,430 cancer patients.
Tu H, McQuade JL, Davies M,. Innov. 2022 Oct 18;3(6):100344. doi: 10.1016/j.xinn.2022.100344.
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma.
Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade, JL, Patel SP, Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M, Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo BA, Bishop AJ, Mitra D, Farooqi A, Bassett R, Faria S, Nagarajan P, Amaria RN. Front Oncol 12:1001150, 2022. e-Pub 10/2022. PMCID: PMC9618687.
Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression.
Mitra D, Farr M, Nagarajan P, Ho J, Bishop AJ, Jhingran A, Farooqi AS, Frumovitz M, Amaria RN, McQuade JL, Jazaeri AA, Guadagnolo BA.Gynecol Oncol. 2022 Dec;167(3):483-489. doi: 10.1016/j.ygyno.2022.09.026. Epub 2022 Oct 11. PMID: 36229264
Obesity is associated with altered tumor metabolism in metastatic melanoma.
Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Gopal Y N V, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JL. Clin Cancer Res. 2022 Sep 27:CCR-22-2661.
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Nature. 2022 Jun;606(7915):797-803. doi: 10.1038/s41586-022-04833-8. Epub 2022 Jun 15. PMID: 35705814
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
Pires da Silva I, Ahmed T, McQuade JL, Nebhan CA, Park JJ, Versluis JM, Serra-Bellver P, Khan Y, Slattery T, Oberoi HK, Ugurel S, Haydu LE, Herbst R, Utikal J, Pföhler C, Terheyden P, Weichenthal M, Gutzmer R, Mohr P, Rai R, Smith JL, Scolyer RA, Arance AM, Pickering L, Larkin J, Lorigan P, Blank CU, Schadendorf D, Davies MA, Carlino MS, Johnson DB, Long GV, Lo SN, Menzies AM. J Clin Oncol. 2022 Apr 1;40(10):1068-1080. doi: 10.1200/JCO.21.01701. Epub 2022 Feb 10. PMID: 35143285
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.
Spencer CN*, McQuade JL*, Gopalakrishnan V*, McCulloch JA*, Vetizou M*, Cogdill AP*, Khan AW*, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloan RS, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G**, Daniel CR**, Wargo JA**. (* co-first author; ** co-last author). Science. 2021 Dec 24;374(6575):1632-1640. doi: 10.1126/science.aaz7015.
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
Andrews MC*, Duong CPM*, Gopalakrishnan V*, Iebba V*, Chen WS*, Derosa L*, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, MA Davies, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L**, Wargo JA**. Nat Med. 2021 Aug;27(8):1432-1441. PMID: 34239137. *Co-first author; **Co-last author
The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
Ogata D, Haydu LE, Glitza IC, Patel SP, Tawbi HA, McQuade JL, Diab A, Ekmekcioglu S, Wong MK, Davies MA, Amaria RN. Cancer Med. 2021 Apr;10(7):2293-2299. doi: 10.1002/cam4.3781. Epub 2021 Mar 8. PMID: 33686688
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, Martínez-Vila C, Wallace R, Bhave P, Reijers ILM, Thompson N, Vanella V, Gerard CL, Aspeslagh S, Labianca A, Khattak A, Mandala M, Xu W, Neyns B, Michielin O, Blank CU, Welsh SJ, Haydon A, Sandhu S, Mangana J, McQuade JL, Ascierto PA, Zimmer L, Johnson DB, Arance A, Lorigan P, Lebbé C, Carlino MS, Sullivan RJ, Long GV, Menzies AM. Ann Oncol 32(7):917-925, 7/2021. PMID: 33798657.
Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis.
Zou F, Wang X, Glitza IC, McQuade JL, Wang J, Zhang HC, Thompson JA, Thomas AS, Wang Y. J Immunother Cancer 9(1), 1/2021. PMID: 33436487. PMCID: PMC7805368
Obesity-induced impairment of antitumor immunity is associated with an immunosuppressive tumor immune landscape.
Pazdrak, B., Mak, D., Damsky, W., Bosenberg, M., Lochmann, B., Gubin, M. and McQuade, J. Cancer Res. 2021 Jul 1;81(13_Supplement), pp.70-70.
Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers.
McQuade JL, Ologun GO, Arora R, Wargo JA. Curr Oncol Rep. 2020 Jun 24;22(7):74. doi: 10.1007/s11912-020-00913-y.
Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers.
McQuade JL, Ologun GO, Arora R, Wargo JA. Curr Oncol Rep. 2020 Jun 24;22(7):74. doi: 10.1007/s11912-020-00913-y.
Gut Microbiome Modulates Response to Cancer Immunotherapy.
Khan MAW, Ologun G, Arora R, McQuade JL, Wargo JA. Dig Dis Sci. 2020 Mar;65(3):885-896. doi: 10.1007/s10620-020-06111-x.
Modulating the microbiome to improve therapeutic response in cancer.
McQuade JL, Daniel CR, Helmink BA, Wargo JA. Lancet Oncol. 2019 Feb;20(2):e77-e91. doi: 10.1016/S1470-2045(18)30952-5.
Modulating the microbiome to improve therapeutic response in cancer.
McQuade JL, Daniel CR, Helmink BA, Wargo JA. Lancet Oncol. 2019 Feb;20(2):e77-e91. doi: 10.1016/S1470-2045(18)30952-5.
A pre-existing rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling.
Romano G, Chen PL, Song P, McQuade J, Liang R, Liu M, Roh W, Duose D, Carapeto F, Li J, The J, Aplin A, Chen M, Zhang J, Lazar A, Davies M, Futreal PA, Amaria R, Zhang D, Wargo J, Kwong L. Cancer Discovery.8(5):556-567, 05/2018. PMID: 29496665 PMCID: PMC5932238
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA. Lancet Oncol. 2018 Mar;19(3):310-322. PMID: 29449192; PMCID: PMC5840029.
Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.
Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Lazar AJ, Wargo JA, Davies MA. Oncoimmunology 6(12). e-Pub 8/2017. PMID: 29209563. PMCID: PMC5706622
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Ann Oncol 28(2):368-376, 2/2017. PMID: 27687304
Mechanisms of resistance and predictors of response in a phase II trial of dabrafenib and trametinib in metastatic melanoma following progression on BRAF inhibitor monotherapy.
Chen G*, McQuade JL*, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jane-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA , Roszik J, Bassett Jr RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. JAMA Oncology. 2016 Aug 1;2(8):1056-64. PMID: 27124486 PMCID: PMC4982774 [*co-first authors]
National Conferences
McQuade J. Can You Manipulation of the Microbiome Improve Melanoma Outcomes and Reduce Treatment-Related Toxicity, 21st Oncology Updates: Advances and Controversies, The University of Texas MD Anderson Cancer Center, Steamboat Springs, CO, 1/20/2025
McQuade J. Mucosal Melanoma: If You Build It They Will Come, The Wistar Institute Peer-reviewed conference presentation, Annual Interskin SPORE Scientific Retreat; Philadelphia, PA, 6/27/2024
McQuade J. Immunotherapy response and toxicity: the role of lifestyle factors SWOG Spring 2024 Group Meeting Invited talk/seminar, Southwest Oncology Group; Seattle, WA, 4/3/2024
McQuade J. Novel Immunotherapy Approach and Targeted Therapy in Melanoma Peer-reviewed conference presentation, 13th Annual Winter Cancer Symposium; Rio Grande, PR, 3/2024
McQuade J. Tumor Infiltrating Lymphocyte Therapy for Disseminated Melanoma: Patient Selection and Novel Strategies, 20th Oncology Updates: Advances and Controversies Invited talk/seminar, Annual CME Meeting; Steamboat Springs, CO, 1/14/2024
McQuade J. Does the Microbiome Influence Breast Cancer Outcomes? 22nd Annual International Congress on the Future of Breast Cancer WEST Invited talk/seminar, Physicians’ Education Resource; San Diego, CA 7/28/2023
McQuade J. Trusting Your Gut: Using the Microbiome to Predict Immunotherapy Response, ASCO Annual Meeting, Chicago, IL, 6/4/2023
McQuade J. Show Me Your Care Plan: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma, PER’s ON Melanoma Satellite Symposium, PERs, San Antonio, TX, 4/29/2023
McQuade J. The interplay of host, tumor, and microbial metabolic phenotypes, AACR Annual Meeting, Orlando, FL, 4/19/2023
McQuade J. Melanoma Research Alliance and Seerave Foundation Melanoma and Microbiome Workshop, Washington DC, DC, Co-Chair, 3/2023
McQuade J. What's the straight Poop on Manipulating the Microbiome in Melanoma Therapy?, 19th annual International Symposium on Melanoma and Other Cutaneous Malignancies, Houston, TX, 2/4/2023
McQuade J. Update on the Role of the Microbiome in the Response to Immunotherapy, 19th Oncology Update: Advances & Controversies, Steamboat Springs, CO, 1/19/2023
McQuade J. Diet, the Microbiome and Immunotherapy Response, AIM at Melanoma/University of Michigan Patient Symposium, Ann Arbor, MI, 10/1/2022
McQuade J. Brain Metastasis Patient Symposium, Microbiome and Diet/survivorship, AIM Foundation, Virtual, 8/27/2022
McQuade J. The microbiome, diet and immunotherapy response: From observation to intervention, American Society of Clinical Oncology, Chicago, IL, 6/6/2022
McQuade J. Diet and the microbiome: From observation to intervention, University of Cincinnati College of Medicine, Grand Rounds, Division of Hematology/Oncology, Cincinnati, OH, 5/20/2022
McQuade J. Unveiling the mysteries of FMT efficacy, European Congress of Clinical Microbiology & Infectious Diseases, Lisbon, Portugal, 4/25/2022
McQuade J. Diet, Microbiota, and Cancer Immunotherapies, AACR 2022 Annual meeting, New Orleans, LA, 4/8/2022
McQuade JL. Lifestyle impacts on immunotherapy, 2021 American Institute for Cancer Research - Virtual Research Conference, 11/2/2021
McQuade JL. The Microbiome and Cancer, The Scripps MD Anderson Cancer Center's 2021 Cancer Care Symposium - Virtual, 11/6/2021
McQuade JL. The obesity paradox: The interplay between host and tumor metabolism, O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Cell, Developmental and Integrative Biology, Birmingham, AL, 10/15/2021
McQuade J. Leveraging other genomes as potential response biomarkers: the microbiome, Immunotherapy Bridge 2020, Virtual, 12/2/2020
McQuade J. Diet and Microbiome, SITC 2020, Milwaukee, WI, 11/11/2020
McQuade J. Diet, the gut microbiome and immune response., Mark Foundation Cancer Research Symposium, New York, NY, 3/3/2020
McQuade J. Microbiome: What to Tell Your Patients., Scripps Clinical Hematology and Oncology 2020, San Diego, CA, 2/17/2020
McQuade J. Diet, the gut microbiome and immune response., ASCO-SITC, Orlando, FL, 2/8/2020
McQuade J. Fiber, the microbiome, and response to immunotherapy: Translation observation to intervention, Obesity, cancer and metabolic diseases working group, Memorial Sloan Kettering, New York, NY, 1/13/2020
McQuade J. Energy Balance in the Era of Immune and Targeted Therapy: Obesity, Diet, and the Microbiome, Obesity, Cancer and Metabolic Diseases Research Group Meeting, MSKCC, New York, NY, 1/13/2020
McQuade J. Energy Balance in the Era of Immune and Targeted Therapy, Medicine Grand Rounds, University of Cincinnati, Cincinnati, OH, 1/10/2020
McQuade J. Fiber and the Microbiome, SITC 2019 34th Annual Meeting & Pre-Conference Programs, National Harbor, MD, 11/10/2019
McQuade J. Microbiome and Cancer: The microbiome and Therapeutic Response in Cancer, Integrative Oncology Advancing the Science & Art of Integrative Oncology 16th International Conference Keynote, New York, NY, 10/20/2019
McQuade J. Diet, the microbiome, and immune checkpoint inhibition, Memorial Sloan Kettering Cancer Center, New York, NY, 10/17/2019
McQuade J. Beyond tumor genomics: Energy balance, melanoma biology, and therapeutic response, Wistar Melanoma Symposium, Philadelphia, PA, 6/1/2019
McQuade J. Energy balance, melanoma biology, and the anti-tumor immune response, Massachusetts General Hospital, Cutaneous Oncology, Boston, MA, 2/5/2019
McQuade JL. Biological mechanisms underlying the obesity paradox in malignant melanoma, Sarcopenia, Cancer, and Near-term Survival: Annual Meeting of the SCANS Research Group, Oakland, CA, 5/30/2018
McQuade J. Obesity and other host factors in melanoma: one-size-doesn't fit all, Oncology Grand Rounds, University of Pittsburgh, Pittsburgh, PA, 5/17/2018
McQuade JL. The Obesity Paradox in Melanoma, Annual Retreat of Skin Cancer SPOREs, New Haven, CT, 7/10/2017
McQuade JL. Obesity in melanoma across the disease continuum, ECOG-ACRIN Spring 2017 Group Meeting, Washington, DC, 5/4/2017
International Conferences
McQuade J. Controlled High Fiber Interventions in Melanoma Patients, The current and the Future, Seerave Retreat, Lisbon, Portugal, 11/20/2024
McQuade J. Patterns of Immune-Related Adverse Events (irAEs) in Adolescent and Young Adult (AYA) Patients with Melanoma Receiving Immune Checkpoint Inhibitors (ICIs), ASCO Annual Meeting; Chicago, IL, 5/31/2024
McQuade J. Obesity and melanoma: The interplay of host and tumor metabolism, The Growing Impact of Obesity on Cancer and Cancer Immunotherapy Outcomes Session, AACR Annual Meeting 2024; San Diego, CA, 4/8/2024McQuade J. Paradoxical Effects of Obesity on Tumor Metabolism and Therapeutic Response Interactions Between Systemic Metabolism and Cancer Metabolism, Society for Immunotherapy of Cancer (SITC) Spring Scientific 2024; Miami, FL, 3/2024
McQuade J. Trusting Your Gut: Using the Microbiome to Predict Immunotherapy Response, ASCO Annual Meeting; Chicago, IL, 6/4/2023
McQuade J. Challenges and opportunities with dietary interventions in patients with cancer, Seerave Foundation Annual Retreat; Amsterdam, Netherlands, 5/2023
McQuade J. The interplay of host, tumor, and microbial metabolic phenotypes, AACR Annual Meeting, Orlando, FL, 4/19/2023
McQuade J. Rationale for nutritional interventions to modulate the microbiome, MRA and Seerave Melanoma and the Microbiome Workshop, Amsterdam, Netherlands, 3/10/2023
McQuade J. Modifiable Host Factors, the Microbiome and Anti-tumor Immunity, Keystone Symposia Cancer Immunotherapy: Mechanisms of Response versus Resistance, Keystone, Keystone, Banff, Canada, 3/8/2023
McQuade J. Fiber, the microbiome, and immunotherapy response, Seerave Retreat, Vienna, Austria, 6/20/2022
McQuade J. Diet, Microbiota, and Cancer Immunotherapies, AACR 2022 Annual meeting; New Orleans, LA, 4/8/2022
McQuade J. Unveiling the mysteries of FMT efficacy, European Congress of Clinical Microbiology & Infectious Diseases, Lisbon, Portugal, 4/25/2022
McQuade J. Nutrition and Metabolism - Possible Implications in Tumor Therapy, Austrian Society of Dermatology and Venereology (ÖGDV), Salzburg, Austria, 11/26/2021
McQuade JL. Modulation of the gut microbiome for therapeutic gain, Focus on Melanoma Virtual Meeting 2021, Cambridge, United Kingdom, 10/15/2021
McQuade JL. Reverse translation in nutrition- from observation to mechanism to intervention, Translating Energy Balance From Bench to Communities: Application of Parallel Animal-Human Studies in Cancer, Virtual, 7/8/2021
McQuade JL. The microbiome, diet, and immune response: From observation to intervention, The MicrobIOta role in the ImmunOncology, Virtual, Italy, 7/14/2021
McQuade JL. The gut microbiome, anti-tumor immunity, and modifiable host factors: From observation to intervention, The 18th International Congress, Society for Melanoma Research - Virtual Meeting, 10/29/2021
McQuade J. Modulation of the gut microbiome for therapeutic gain, Melanoma Focus, Cambridge, United Kingdom, 10/15/2021
McQuade J. The obesity paradox: From host to tumor metabolism, Transdisciplinary Research on Energetics and Cancer (TREC) webinar, Virtual, 9/22/2021
McQuade J. The microbiome, diet, and immune response: From observation to intervention, The MicrobIOta role in the ImmunOncology, Virtual, Italy, 7/14/2021
McQuade J. Reverse translation in nutrition- from observation to mechanism to intervention, Translating Energy Balance From Bench to Communities: Application of Parallel Animal-Human Studies in Cancer, Virtual, 7/8/2021
McQuade J. The Microbiome, Diet, and Immune Response: From Observation to Intervention, 17th Annual Oncology Research & Education Day, Virtual, Canada, 6/14/2021
McQuade JL. The microbiome, diet, and immune response: From observation to intervention, Western University, 2nd Annual Immuno-Oncology Symposium - Virtual Meeting, London, Ontario, Canada, 2/9/2021
McQuade J. Leveraging other genomes as potential response biomarkers: the microbiome, Immunotherapy Bridge 2020, Virtual, 12/2/2020
McQuade J. Diet, energy balance and the gut microbiome., Victorian Comprehensive Cancer Centre, Victoria, Australia, Virtual, 10/26/2020
McQuade J. Diet, the microbiome, and immune response: From observation to intervention, 28th IMWG, Virtual, 7/14/2020
McQuade J. Microbiome and immunotherapy., SEOM Immunotherapy Symposium '20, Madrid, Spain, 2/21/2020
McQuade J. Fiber and immunotherapy response: Human Data., Emergence-Mini-Symposium: Metabolism & Nutrition in cancer prevention and treatment: from basic science to interventions., Gustave Roussy Institute, Paris, France, 1/31/2020
McQuade J. The microbiome and personalized immunotherapy., Prague ONCO 2020, Prague, Czech Republic, 1/30/2020
McQuade J. Obesity, microbiome, diet and immunotherapy, Current Trends in Immuno-Oncology, Sydney, 3/15/2019
McQuade J. Nutrition vs the Microbiota: Nutrition, Immunotherapy Bridge, Naples, Italy, 12/5/2019